Welcome to our dedicated page for Celularity SEC filings (Ticker: CELU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celularity Inc. filings document material events, governance matters, capital-structure disclosures and operating results for a regenerative and cellular medicine company. The record includes Form 8-K reports on material agreements, executive changes and compensation arrangements, along with security disclosures covering Class A common stock and CELUW warrants.
Celularity's proxy materials address director elections, auditor ratification, equity incentive plan amendments and shareholder voting procedures. The filings also cover clinical or regulatory disclosures tied to the company's cell-therapy and regenerative medicine activities, as well as reporting-status matters affecting its Nasdaq listing compliance.
Celularity Inc. director Vincent LeVien reported receiving 28,847 restricted stock units (RSUs) of Class A common stock under the company’s 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of Class A common stock, and the filing states that these RSUs vest immediately upon grant as of 01/12/2026. After this equity award, LeVien beneficially owns 153,847 shares of Celularity Class A common stock in total, held directly.
Celularity Inc. reported that director Geoffrey Ling received a grant of 19,231 restricted stock units (RSUs) under the company’s 2021 Equity Incentive Plan on January 12, 2026. Each RSU represents one share of Celularity’s Class A common stock, and the RSUs vest immediately upon grant, meaning the shares are no longer subject to a vesting schedule. Following this equity award, Ling now beneficially owns 256,026 shares of Celularity Class A common stock in total, reflecting a routine update to his equity-based director compensation.
Celularity Inc. director Geoffrey Ling reported receiving 19,231 restricted stock units (RSUs) of Class A common stock. These RSUs were granted under the company’s 2021 Equity Incentive Plan at no cash cost and each unit represents one future share. The RSUs will vest on the earlier of one year from the grant date or the next annual stockholder meeting, as long as he continues serving the company. After this award, Ling beneficially owns 256,026 shares and RSUs in total on a direct basis.
Celularity Inc. director Vincent LeVien reported an award of 28,847 shares of Class A common stock on January 12, 2026, coded as an "A" transaction for an acquisition at a price of $0 per share. These shares are in the form of restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Class A common stock.
The RSUs will vest and become exercisable on the earlier of the one-year anniversary of the grant date and the next annual stockholder meeting, as long as LeVien continues to provide service to the company through that date. Following this grant, he beneficially owns a total of 153,847 shares of Class A common stock in direct ownership.
Celularity Inc. director Peter Diamandis reported an equity award of 20,385 restricted stock units (RSUs) of Class A common stock on January 12, 2026. The RSUs were granted at a price of $0 per share under the Celularity Inc. 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Class A common stock.
The RSUs will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, as long as Diamandis continues to serve the company through that date. Following this grant, he directly holds a total of 394,150 Class A common shares and RSUs.
Celularity Inc. director Diane L. Parks received an award of 30,000 restricted stock units (RSUs) of Class A common stock on January 12, 2026, reported at a grant price of $0 per share. Each RSU represents the right to receive one share of Class A common stock.
The RSUs vest on the earlier of the one-year anniversary of the grant date and the next annual stockholder meeting, if she continues serving the company through that date. Following this grant, she beneficially owns 520,021 shares of Class A common stock, including the new RSUs granted under the 2021 Equity Incentive Plan.
Celularity Inc. (CELU) reported an equity award to a director. Director Diane Parks received 61,539 restricted stock units (RSUs) of Class A common stock on 11/19/2025 under the Celularity Inc. 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of Class A common stock, and the RSUs vest and become exercisable on the grant date at a price of $0.00 per share. Following this grant, Diane Parks beneficially owns 365,021 shares of Celularity Class A common stock in direct ownership.
Celularity Inc. (CELU) reported a new equity grant to a director. On 11/19/2025, the reporting person, who serves as a director of Celularity, received 3,699 shares of Class A common stock in the form of restricted stock units (RSUs) under the Celularity Inc. 2021 Equity Incentive Plan.
Each RSU represents a right to receive one share of Celularity's Class A common stock, and the RSUs vest and become exercisable on the date of grant. After this transaction, the director beneficially owns 3,699 Class A common shares directly.
Celularity Inc. (CELU) director Geoffrey Ling reported a grant of 44,379 restricted stock units (RSUs). The transaction occurred on 11/19/2025 and was reported on a Form 4 as an acquisition of Class A common stock at a stated price of $0.00 per share, reflecting an equity award rather than an open-market purchase.
Each RSU represents the right to receive one share of Celularity’s Class A common stock, and the RSUs vest and become exercisable on the grant date under the company’s 2021 Equity Incentive Plan. Following this award, Ling beneficially owns 111,795 shares of Class A common stock in direct form, aligning his interests more closely with those of shareholders.
Celularity Inc. (CELU) director Peter Diamandis reported an equity award of 47,042 restricted stock units (RSUs) of Class A common stock. Each RSU represents the right to receive one share of Celularity's Class A common stock. The RSUs were granted on 11/19/2025 under the Celularity Inc. 2021 Equity Incentive Plan and shall vest and become exercisable on the grant date, meaning they are not subject to a future service-based vesting schedule. The Form 4 shows the transaction price as $0.00, consistent with a typical director equity grant rather than an open-market purchase. Following this grant, Diamandis is reported to beneficially own 248,765 shares of Class A common stock in direct ownership.